Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TPST Stock  USD 0.93  0.03  3.33%   
Slightly above 58% of all Tempest Therapeutics' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that some traders are interested. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
BRISBANE, Calif., Sept. 05, 2024 -- Tempest Therapeutics, Inc. , a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Sam Whiting, M.D., Ph.D., chief medical officer and head of RD at Tempest, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The company presentation will be available for on-demand viewing Monday, September 9, 2024, at 700 a.m.

Read at finance.yahoo.com
Yahoo News
  

Tempest Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Tempest Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Tempest Therapeutics Fundamental Analysis

We analyze Tempest Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash And Equivalents

Cash And Equivalents Comparative Analysis

Tempest Therapeutics is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Tempest Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tempest Therapeutics stock to make a market-neutral strategy. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with similar companies.

Peers

Tempest Therapeutics Related Equities

ARMPArmata Pharmaceuticals   8.74   
0%
88.0%
RNXTRenovoRx   6.38   
0%
64.0%
INDPIndaptus Therapeutics   2.38   
0%
24.0%
RZLTRezolute   2.31   
0%
23.0%
CGEMCullinan Oncology   1.56   
0%
15.0%
ZNTLZentalis Pharmaceuticals   0.45   
0%
4.0%
RVMDRevolution Medicines   0.32   
3.0%
0%
IKNAIkena Oncology   0.66   
6.0%
0%
AKTXAkari Therapeutics   0.83   
8.0%
0%
FBRXForte Biosciences   1.27   
12.0%
0%
LYELLyell Immunopharma   1.72   
17.0%
0%
GLUEMonte Rosa   1.74   
17.0%
0%
ANEBAnebulo Pharmaceuticals   1.85   
18.0%
0%
OLMAOlema Pharmaceuticals   2.83   
28.0%
0%
SANASana Biotechnology   7.59   
76.0%
0%
PCSAProcessa Pharmaceuticals   9.88   
100.0%
0%

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.